Login
$NEO
$15.41 +$0.00 (0.0%) After hours

$NEO 8-K SEC Filings

Filed On Filing
28 Oct 2026 8-K: Results of Operations and Financial Condition

Fort Myers, Florida (October 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third-quarter results for the period ended ...

05 Oct 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

FORT MYERS, Fla.—NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession its Board of Dire...

11 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

28 Jul 2026 8-K: Results of Operations and Financial Condition

Fort Myers, Florida (July 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended Ju...

20 Jul 2026 8-K: Regulation FD Disclosure; Other Events

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the De...

25 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors.

22 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE dated as of June 22, 2026 between NEOGENOMICS, INC., a Nevada corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as...

17 Jun 2026 8-K: Other Events

FORT MYERS, Fla., June 17, 2026—NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million...

15 Jun 2026 8-K: Other Events

FORT MYERS, Fla., June 15, 2026—NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate princ...

22 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

28 Apr 2026 8-K: Results of Operations and Financial Condition

Fort Myers, Florida (April 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first quarter results for the period ended Ma...

17 Feb 2026 8-K: Results of Operations and Financial Condition

Fort Myers, Florida, (February 17, 2026) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full year results for ...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

– Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million –

30 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

FORT MYERS, Fla., December 30, 2025—NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment diagnostics and lab services industry veteran John P...

28 Oct 2025 8-K: Results of Operations and Financial Condition

Fort Myers, Florida (October 28, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended ...

08 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

29 Jul 2025 8-K: Results of Operations and Financial Condition

Fort Myers, Florida (July 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended Ju...

24 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

FORT MYERS, Fla., June 24, 2025—NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective J...

27 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

29 Apr 2025 8-K: Results of Operations and Financial Condition

Fort Myers, Florida (April 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended Ma...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support